MELBOURNE, Australia, June 25 /PRNewswire-FirstCall/ -- Phosphagenics
Limited (ASX: POH) (AIM: PSG) (ADR/OTC: PPGNY) announced today positive
results from pre-clinical studies of its TPM-02 dermal drug delivery
technology formulated with retinoic acid, a leading topical treatment for
severe acne and an active ingredient used in anti-aging cosmetics.
The proof of concept studies showed a three-fold increase in the amount
of retinoic acid delivered into the skin when formulated with TPM-02
compared to a control formulation. Importantly, there was no retinoic acid
detected in the bloodstream. TPM-02's ability to deliver an active
ingredient to the dermis, the active layer of the skin, highlights the
system's potential use in dermatologic and cosmetic products.
This study builds upon Phosphagenics' successes in delivering drugs,
including insulin, through the skin without causing skin irritation, and
further demonstrates that the TPM-02 technology can be utilized to deliver
and hold an active ingredient in the skin, which is optimal in achieving
maximum effectiveness from dermatological and cosmetic products.
"These proof of concept studies demonstrate the adaptability and
flexibility of Phosphagenics' delivery technology, and we intend to
leverage these results in pursuing opportunities in the dermatological and
cosmetic fields," said Dr. Esra Ogru, Executive Vice President R&D at
Phosphagenics. "The ability to deliver greater amounts of retinoic acid to
the skin will produce more effective products for consumers, which is our
objective in the areas of dermatology and cosmetics."
In addition to improving the dermal delivery of retinoic acid,
Phosphagenics sees broader applications for its TPM-02 technology with
additional pre-clinical studies showing potential in the dermal delivery of
other compounds, such as coenzyme Q10 (CoQ10) and omega-3 fatty acids.
About Phosphagenics Limited
Phosphagenics is a Melbourne-based, globally driven biotechnology
company focused on the discovery of new and cost effective ways to enhance
the bioavailability, activity, safety and delivery of proven pharmaceutical
and nutraceutical products. The Company's core technology is built around
the science and application of phosphorylation, a process where the
addition of a phosphate group has been found to enhance the
bioavailability, activity and safety of existing pharmaceuticals and
nutraceuticals, as well as to assist in the production of drug delivery
platforms. Phosphagenics' shares are listed on the Australian Stock
Exchange (POH) and the London Stock Exchange's Alternative Investment
Market (PSG). An ADR -- Level 1 program has been established in the US with
the Bank of New York (PPGNY) for US investors to trade in Phosphagenics'
stock on the "over-the-counter" market.
For more information, please visit Phosphagenics' web site at
SOURCE Phosphagenics Limited